Table 4.
Adjusted hazard ratios of cancer risk (all sites combined) subsequent to benign tumors (all sites combined) in the myotonic dystrophy type I (DM1)‐affected and DM1‐free cohorts, stratified by age at DM1 diagnosis.
| Cohort | Classic DM1 (age at diagnosis = 11–40 years) | Late‐onset DM1 (age at diagnosis >40 years) | ||||||
|---|---|---|---|---|---|---|---|---|
| HR1 | 95% CI | P‐value | HR1 | 95% CI | P‐value | |||
| DM1‐affected | 2.7 | 0.93 | 7.59 | 0.07 | 0.7 | 0.15 | 3.38 | 0.67 |
| Matched DM1‐free controls | 1.2 | 0.70 | 2.08 | 0.50 | 2.0 | 1.47 | 2.63 | <0.001 |
| P‐heterogeneity = 0.01 | P‐heterogeneity = 0.12 | |||||||
No cancers were observed subsequent to benign tumors in congenital/childhood DM1 patients or their matched controls.
1
Hazard ratios of subsequent cancer comparing patients with benign tumors to those who are tumor‐free; models were adjusted for gender and number of healthcare care encounters.